Purpose: BCR-ABL + B-ALL leukemic cells are highly dependent on the expression of endogenous anti-apoptotic MCL-1 to promote viability and are resistant to BH3-mimetic agents such as navitoclax (ABT-263) that targets BCL-2, BCL-XL, and BCL-W. However, the survival of most normal blood cells and other cell types are also dependent on Mcl-1.
Introduction
One in five pediatric patients with acute lymphoblastic leukemia (ALL) are diagnosed with poor prognosis disease (including BCR-ABL + ALL) (1) . Adults with ALL have even poorer survival rates (<40%) in part due to the dominant role of the BCR-ABL oncogene (2) . In Philadelphia chromosome (Ph + ) leukemia, BCR-ABL fusion proteins encode constitutively-active tyrosine kinases (e.g. p185 in B-ALL and p210 in chronic myelogenous leukemia, CML) essential for cell transformation (3, 4) . CML therapy has been revolutionized by the BCR-ABL tyrosine kinase inhibitors (TKIs), which induce and maintain remission without serious side effects (5) . In contrast, TKI treatment of Ph + B-ALL results in short remissions and rapid outgrowth of TKI-resistant clones (6, 7) . As a result, Ph + ALL patients require intensive chemotherapy and stem cell transplants (1).
Thus, new therapies are needed to improve patient outcomes.
Leukemic cells often feature the elevated expression of anti-apoptotic molecules that inhibit cell death by preventing BAX and BAK-dependent mitochondrial outer membrane permeabilization and caspase activation. Small molecule inhibitors, known as BH3-mimetics, including nativoclax (ABT-263) and venetoclax (ABT-199), have been developed to inhibit the anti-apoptotic molecules BCL-2, BCL-XL, BCL-W or only BCL-2 respectively (8, 9) . These agents are effective because malignant cells often become addicted to the function of anti-apoptotic BCL-2 members to permit their survival, thus making them more sensitive to inhibitors of this pathway than normal cells (10) . is approved for treatment of some chronic lymphocytic leukemia with a 17p deletion. In contrast, ABT-263 is still in development with the caveat that it provokes a dose-limiting thrombocytopenia due to the on-target effect of inhibiting BCL-XL in platelets (11). While
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Author Manuscript Published OnlineFirst on October 3, 2017; DOI: 10.1158/1078-0432.CCR- these BH3-mimetics show promise in treating malignancies, elevated anti-apoptotic MCL-1 expression represents a common resistance mechanism (12) (13) (14) (15) . MCL-1 levels are commonly elevated in cancer, but potent MCL-1 inhibitors are still in development (16, 17) . MCL-1 is unique among pro-survival molecules in that it is essential for development and for the survival of many cellular lineages (18) . Hence, it is still unclear whether effective MCL-1 inhibition during standard cancer therapy will result in toxic side effects in humans. 
Materials and Methods

Plasmids, Expression Constructs, and Generation of Mutants. BCR-ABL (p185)
plasmid was from Dr. Witte (UCLA, CA) and BCR-ABL T315I mutant was generated by site-directed mutagenesis. Murine Mcl-1 cDNA was stably expressed in leukemic cells by retroviral transduction.
Ecotropic Retroviral Production and Cell Transduction. Retroviruses were produced as previously described (19) . Stable cells were generated by retroviral transduction and drug selection or by fluorescent activated cell sorting. acquired on a LI-COR Odyssey (LI-COR, NB) and densitometry assessed for all blots in replicate for statistical analysis (Sup. Fig. 7 ).
Microarray Analysis and GSEA. Affymetrix Mouse Gene 2.0 ST arrays were used to assay RNA samples. Data was submitted to NIH GEO Accession number: GSE95809. The 4-hour DHA treated samples were statistically tested by unequal variance t test to the DMSO control (3 replicates) and the volcano plot was generated by converting the resultant pvalue to a score (-log10(pvalue)) using Spotfire (TIBCO, CA). Gene set enrichment analysis (GSEA) (version 2.2.3) was performed using 4-hour DHA samples vs. DMSO control samples and the c5.all.v5.2 symbol.gmt Gene Ontology gene sets. Gene set permutation was performed 1000 times using the weighted enrichment statistic and genes ranked by signal to noise metric. A library of approved drugs were screened to identify compounds that killed mouse BCR-ABL + B-ALL leukemic cells (30) . This screen identified members of the artemisinin class of anti-malarial agents including dihydroartemisinin (DHA), a widely-used, orallydelivered drug for malaria with favorable pharmacokinetics and bioavailability in humans (31) . DHA possesses anti-cancer properties; however, the mechanism(s) by which DHA functions to kill cancer cells is unclear (32) (33) (34) (35) (36) . set induced by DHA repression correlates significantly with known endoplasmic reticulum (ER) stress pathway signatures ( Fig. 2A) . The induction of these genes was confirmed by quantitative PCR and immunoblot analysis for CHOP, which is encoded by the Ddit3 gene (Sup. Fig. 3B and Fig. 2B ). Even when the cells were treated with ROS scavengers, ER stress markers were induced by DHA treatment (Sup. Fig. 2E) . Furthermore, the induction of the BH3-only gene Pmaip1, which encodes the pro-apoptotic protein NOXA, was 
Cell
DHA synergizes with ABT-263 in killing murine BCR-ABL + B-ALL cells.
Resistance to tyrosine kinase inhibitors (TKI) is a significant barrier to treatment of both Ph + CML and Ph + ALL (6, 7, 41, 42) . Therefore, TKI-resistant mouse leukemic cell lines were generated using a common "gate keeper" mutation (BCR-ABL for in vitro synergy. Leukemic cells were isolated from the recipient mice and subjected to treatment with DHA and/or ABT-263 in culture. While both PDX samples were sensitive to single agent ABT-263, they were quite resistant to cell death induced by DHA alone. However, the killing by low dose ABT-263 synergized with DHA in both PDX models (Fig. 4C&D) . Response surface modeling indicated synergy of both primary patient xenografts PDX10940 and (α=118; p=2.64×10 -10 ) and PDX10380 (α=13667; p=2.67×10 -5 ). These data indicate that combining DHA with ABT-263 can potentiate the response of primary patient leukemia when treated in culture. Future studies will be necessary to determine whether the combination therapy can be similarly efficacious when delivered in vivo to NSG-mice bearing luciferase-labeled human PDX Ph + leukemia.
on resulting from the transplanted cells was highly aggressive, replacing normal hematopoiesis in the bone marrow. Furthermore, the leukemic cells invaded the central nervous system and lymphatics and often resulted in hind-limb paralysis (Sup. Fig. 6C ).
The resultant leukemic cells expressed B220 + cell surface marker and were Pax5 + (Sup. Fig. 6D ).
Despite the extension of survival over the 15 days of treatment, all mice, including those in the combination treated group, eventually succumbed to leukemia ( 
mice bearing Ph + primary patient leukemia will reveal similarly synergistic responses and MCL-1 repression.. Furthermore, we are also investigating whether this mechanism might be common to other tumor and leukemia types. Importantly, in leukemic cells DHA may have the added benefit that it bypasses resistance to kinase inhibitors that would be expected to occur in the clinic. Therefore, our data indicate that DHA represents an additional strategic pathway by which MCL-1 expression can be repressed leading to enhanced response in poor prognosis BCR-ABL + B-ALL.
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